26 May, 2017
Physicians Financial Services Inc. boosted its position in Teva Pharmaceutical Industries by 8.1% in the third quarter.
Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Teva Pharmaceutical Industries Limited the EPS stands at 1.06 for the previous quarter, while the analysts predicted the EPS of the stock to be 1.03, suggesting the stock exceeded the analysts' expectations. SOL Capital Management CO raised its position in Teva Pharmaceutical Industries by 5.8% in the third quarter.
Sphera Funds Management Ltd increased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 29.85% based on its latest 2016Q4 regulatory filing with the SEC. They are projecting Next Quarter growth of -4.6%. This recommendation lands on a scale between 1 and 5.
More notable recent Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) news were published by: Investorplace.com which released: "Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Is a Good Spec Buy" on March 08, 2017, also Benzinga.com with their article: "Vetr Issues Strong Buy As Teva Trends Down" published on May 19, 2017, Investorplace.com published: "Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Going to $40" on May 24, 2017. JFS Wealth Advisors LLC now owns 2,495 shares of the company's stock worth $115,000 after buying an additional 1,451 shares during the last quarter.
But making Teva Pharmaceutical Industries Ltd an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of TEVA entered into oversold territory, changing hands as low as $28.495 per share.
The Relative Volume of the company is 2.13 and Average Volume (3 months) is 6.78 million. The stock's 50-day moving average price is $31.22 and its 200 day moving average price is $34.30.
Teva Pharmaceutical Industries Limited closed its last trading session at $28.76 with the gain of 0.76%. The stock has a market cap of $29.44 billion, a P/E ratio of 371.54 and a beta of 0.58. Teva Pharmaceutical Industries also was the recipient of unusually large options trading on Wednesday. Investors purchased 963 put options on the stock. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned "Buy" rating by Oppenheimer on Friday, April 7. During the same quarter in the prior year, the company earned $1.20 earnings per share. Presently, it has a Return on Equity (ROE) of 0.30% and Return on Investment (ROI) of 1.10%. The business had revenue of $5.63 billion for the quarter, compared to analyst estimates of $5.69 billion. During the same period a year ago, the company posted $1.20 earnings per share. The company's revenue for the quarter was up 17.0% compared to the same quarter a year ago. Teva Pharmaceutical Industries Limited (TEVA) has made its way to a 12-month decline of -44.15%.
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 22nd. Shareholders of record on Monday, June 5th will be given a $0.34 dividend. The ex-dividend date is Thursday, June 1st. This represents a $1.36 annualized dividend and a yield of 4.69%.
Price to Sale ratio of TEVA stands at 1.29 while Price to Book Ratio stands at 0.96. Stratos Wealth Partners LTD. raised its position in Teva Pharmaceutical Industries by 17.4% in the third quarter. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and worldwide trademark and copyright law. The original version of this report can be viewed at [[permalink]].
Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. set a $37.00 price objective on Teva Pharmaceutical Industries and gave the stock a "hold" rating in a research report on Friday, February 17th. On Wednesday, November 16 the stock rating was maintained by Mizuho with "Neutral". Finally, Citigroup Inc reissued a "buy" rating and set a $47.00 price target on shares of Teva Pharmaceutical Industries in a research report on Tuesday, February 7th. Finally, Maxim Group cut their price target on Teva Pharmaceutical Industries from $41.00 to $40.00 and set a "hold" rating on the stock in a research note on Monday, February 13th.